Cargando…

Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy

ABSTRACT: Atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G) have been linked to mutations in many of the proteins that are involved in alternative complement pathway activation. Age and etiology confounded, the prevalence of such mutations has been reported to be over 30 to 50% i...

Descripción completa

Detalles Bibliográficos
Autores principales: Haydock, Ludwig, Garneau, Alexandre P., Tremblay, Laurence, Yen, Hai-Yun, Gao, Hanlin, Harrisson, Raphaël, Isenring, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770394/
https://www.ncbi.nlm.nih.gov/pubmed/34714369
http://dx.doi.org/10.1007/s00109-021-02102-1
_version_ 1784635361231634432
author Haydock, Ludwig
Garneau, Alexandre P.
Tremblay, Laurence
Yen, Hai-Yun
Gao, Hanlin
Harrisson, Raphaël
Isenring, Paul
author_facet Haydock, Ludwig
Garneau, Alexandre P.
Tremblay, Laurence
Yen, Hai-Yun
Gao, Hanlin
Harrisson, Raphaël
Isenring, Paul
author_sort Haydock, Ludwig
collection PubMed
description ABSTRACT: Atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G) have been linked to mutations in many of the proteins that are involved in alternative complement pathway activation. Age and etiology confounded, the prevalence of such mutations has been reported to be over 30 to 50% in these diseases. However, the cohorts studied included many children or individuals with a familial history of complement-related disorders and genetic tests were usually limited to exome sequencing of known causative or risk-associated genes. In this study, a retrospective adult cohort of 35 patients with biopsy-proven thrombotic microangiopathy (the largest in Canada) and 10 patients with C3 glomerulopathy was tested through an extended exome panel to identify causative defects in associated or candidate genes including those of the alternative and terminal complement pathways. A variant of unknown significance was also analyzed for pathogenicity through in vitro studies. To our surprise, the prevalence of known causative or risk-associated variants in either of these cohorts was found to be less than ~ 15% overall. However, the panel used and analyses carried out allowed to identify novel variants of potential clinical significance and a number of candidate genes. The prevalence of known genetic defects in adult-onset aHUS and C3G is thus probably much lower than 30 to 50%. Our results also point towards the importance of investigating diseases of the alternative complement pathway through extended exome panels and in vitro analyses. KEY MESSAGES: The alternative complement pathway plays a major role in the pathogenesis of hemolytic uremic syndrome and C3 glomerulopathy. Based on previous studies, both disorders have been commonly linked to variants in the various intermediates that sustain or regulate this pathway. The prevalence of such mutations in the adult-onset and sporadic forms of these diseases is probably much lower than expected based on larger series. The sporadic forms of complementopathies are likely to involve additional genes that are yet to be uncovered. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00109-021-02102-1.
format Online
Article
Text
id pubmed-8770394
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-87703942022-02-02 Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy Haydock, Ludwig Garneau, Alexandre P. Tremblay, Laurence Yen, Hai-Yun Gao, Hanlin Harrisson, Raphaël Isenring, Paul J Mol Med (Berl) Original Article ABSTRACT: Atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G) have been linked to mutations in many of the proteins that are involved in alternative complement pathway activation. Age and etiology confounded, the prevalence of such mutations has been reported to be over 30 to 50% in these diseases. However, the cohorts studied included many children or individuals with a familial history of complement-related disorders and genetic tests were usually limited to exome sequencing of known causative or risk-associated genes. In this study, a retrospective adult cohort of 35 patients with biopsy-proven thrombotic microangiopathy (the largest in Canada) and 10 patients with C3 glomerulopathy was tested through an extended exome panel to identify causative defects in associated or candidate genes including those of the alternative and terminal complement pathways. A variant of unknown significance was also analyzed for pathogenicity through in vitro studies. To our surprise, the prevalence of known causative or risk-associated variants in either of these cohorts was found to be less than ~ 15% overall. However, the panel used and analyses carried out allowed to identify novel variants of potential clinical significance and a number of candidate genes. The prevalence of known genetic defects in adult-onset aHUS and C3G is thus probably much lower than 30 to 50%. Our results also point towards the importance of investigating diseases of the alternative complement pathway through extended exome panels and in vitro analyses. KEY MESSAGES: The alternative complement pathway plays a major role in the pathogenesis of hemolytic uremic syndrome and C3 glomerulopathy. Based on previous studies, both disorders have been commonly linked to variants in the various intermediates that sustain or regulate this pathway. The prevalence of such mutations in the adult-onset and sporadic forms of these diseases is probably much lower than expected based on larger series. The sporadic forms of complementopathies are likely to involve additional genes that are yet to be uncovered. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00109-021-02102-1. Springer Berlin Heidelberg 2021-10-29 2022 /pmc/articles/PMC8770394/ /pubmed/34714369 http://dx.doi.org/10.1007/s00109-021-02102-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Haydock, Ludwig
Garneau, Alexandre P.
Tremblay, Laurence
Yen, Hai-Yun
Gao, Hanlin
Harrisson, Raphaël
Isenring, Paul
Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy
title Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy
title_full Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy
title_fullStr Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy
title_full_unstemmed Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy
title_short Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy
title_sort genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and c3 glomerulopathy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770394/
https://www.ncbi.nlm.nih.gov/pubmed/34714369
http://dx.doi.org/10.1007/s00109-021-02102-1
work_keys_str_mv AT haydockludwig geneticabnormalitiesinbiopsyprovenadultonsethemolyticuremicsyndromeandc3glomerulopathy
AT garneaualexandrep geneticabnormalitiesinbiopsyprovenadultonsethemolyticuremicsyndromeandc3glomerulopathy
AT tremblaylaurence geneticabnormalitiesinbiopsyprovenadultonsethemolyticuremicsyndromeandc3glomerulopathy
AT yenhaiyun geneticabnormalitiesinbiopsyprovenadultonsethemolyticuremicsyndromeandc3glomerulopathy
AT gaohanlin geneticabnormalitiesinbiopsyprovenadultonsethemolyticuremicsyndromeandc3glomerulopathy
AT harrissonraphael geneticabnormalitiesinbiopsyprovenadultonsethemolyticuremicsyndromeandc3glomerulopathy
AT isenringpaul geneticabnormalitiesinbiopsyprovenadultonsethemolyticuremicsyndromeandc3glomerulopathy